International Research Journal of Education and Technology
Peer Reviewed Journal
ISSN 2581-7795

Genomic and non-genomic pathway of serum Vitamin D among Diabetic Nephropathy patients .

Dr Anamika Singh Rathore, Research Scholar, Malwanchal University, Indore

Dr Sherya Nighoskar, Research Supervisor, Malwanchal University, Indore

Introduction

Diabetic nephropathy (DN) is a common complication of diabetes mellitus, characterized by progressive kidney damage that can lead to end-stage renal disease (ESRD). The pathogenesis of DN involves complex interactions between genetic, metabolic, and hemodynamic factors. Vitamin D, traditionally known for its role in calcium and phosphorus homeostasis, has emerged as a potential modulator of various non-skeletal functions, including immune regulation, cell proliferation, and differentiation. Recent studies have highlighted the potential role of Vitamin D in the pathophysiology of DN through both genomic and non-genomic pathways.

Vitamin D Metabolism

Vitamin D exists in two main forms: Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol). Vitamin D3 is synthesized in the skin upon exposure to ultraviolet B (UVB) radiation and can also be obtained from dietary sources. Both forms of Vitamin D undergo hydroxylation in the liver to form 25-hydroxyvitamin D [25(OH)D], the major circulating form of Vitamin D. Further hydroxylation in the kidneys produces the biologically active form, 1,25-dihydroxyvitamin D [1,25(OH)2D].

Genomic Pathway of Vitamin D

The genomic actions of Vitamin D are primarily mediated through the Vitamin D receptor (VDR), a member of the nuclear receptor superfamily. Upon binding to 1,25(OH)2D, the VDR forms a heterodimer with the retinoid X receptor (RXR). This complex then binds to Vitamin D response elements (VDREs) in the promoter regions of target genes, leading to the modulation of gene transcription. The VDR is expressed in various tissues, including the kidneys, pancreas, and immune cells, indicating a broad range of potential biological effects.

Genomic Pathway in Diabetic Nephropathy

In the context of DN, the genomic actions of Vitamin D may influence several key pathological processes:

1. **Inflammation:** Vitamin D has been shown to modulate the expression of inflammatory cytokines and chemokines. For instance, it can suppress the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) while enhancing the production of anti-inflammatory cytokines like interleukin-10 (IL-10). These effects are mediated through the VDR in immune cells, potentially reducing renal inflammation in DN.
2. **Fibrosis:** The progression of DN is characterized by renal fibrosis, involving the excessive deposition of extracellular matrix (ECM) proteins. Vitamin D can inhibit the expression of fibrotic markers such as transforming growth factor-beta (TGF-β) and fibronectin. This antifibrotic effect is partly mediated by the VDR, which can directly regulate the transcription of genes involved in ECM production.
3. **Cell Proliferation and Apoptosis:** Vitamin D can modulate cell proliferation and apoptosis in renal cells. It has been shown to inhibit the proliferation of mesangial cells and reduce glomerular hypertrophy, both of which are hallmarks of DN. Additionally, Vitamin D can induce apoptosis in tubular epithelial cells through VDR-mediated pathways, potentially limiting tubular atrophy and interstitial fibrosis.

Non-Genomic Pathway of Vitamin D

In addition to its genomic actions, Vitamin D can exert rapid, non-genomic effects through membrane-associated receptors and signaling pathways. These non-genomic actions are independent of gene transcription and typically involve the activation of intracellular signaling cascades.

Non-Genomic Pathway in Diabetic Nephropathy

The non-genomic actions of Vitamin D in DN involve several key mechanisms:

1. **Calcium Homeostasis:** Vitamin D can modulate calcium homeostasis through rapid, non-genomic effects on calcium channels and transporters. It can enhance calcium

reabsorption in the kidneys, which is critical for maintaining calcium balance in DN patients who often exhibit altered calcium metabolism.

2. **Protein Kinase Activation:** Vitamin D can activate various protein kinases, including protein kinase C (PKC) and mitogen-activated protein kinases (MAPKs). These kinases play essential roles in cell signaling and can influence processes such as cell proliferation, differentiation, and apoptosis. In DN, the activation of PKC and MAPKs by Vitamin D may help mitigate renal injury and fibrosis.
3. **Renin-Angiotensin System (RAS) Modulation:** The RAS is a key regulator of blood pressure and fluid balance, and its dysregulation is implicated in the progression of DN. Vitamin D can inhibit renin expression through non-genomic mechanisms, thereby reducing the activity of the RAS and alleviating hypertension and renal damage in DN patients.

Clinical Implications and Therapeutic Potential

The dual pathways of Vitamin D action—genomic and non-genomic—highlight its potential as a therapeutic agent in DN. Several clinical studies have explored the effects of Vitamin D supplementation in DN patients, with promising results:

1. **Reduction in Albuminuria:** Albuminuria is a hallmark of DN and a predictor of disease progression. Vitamin D supplementation has been shown to reduce albuminuria in DN patients, likely through its anti-inflammatory, antifibrotic, and renoprotective effects.
2. **Improvement in Renal Function:** Some studies have reported improvements in glomerular filtration rate (GFR) and other markers of renal function in DN patients treated with Vitamin D. These effects may be mediated by both genomic and non-genomic pathways, including the modulation of inflammation, fibrosis, and calcium homeostasis.
3. **Cardiovascular Protection:** DN patients are at increased risk of cardiovascular disease (CVD), and Vitamin D has been shown to exert cardioprotective effects. By modulating the RAS, reducing inflammation, and improving endothelial function, Vitamin D may help reduce the cardiovascular burden in DN patients.

Conclusion

The intricate interplay between genomic and non-genomic pathways of Vitamin D underscores its multifaceted role in the pathophysiology of DN. Through its actions on inflammation, fibrosis, cell proliferation, apoptosis, calcium homeostasis, and the RAS, Vitamin D emerges as a potential therapeutic agent for DN. Further research is needed to elucidate the precise mechanisms of these pathways and to optimize Vitamin D-based interventions for DN patients. The growing body of evidence supports the notion that maintaining adequate Vitamin D levels could be beneficial in managing and potentially slowing the progression of DN, offering hope for improved outcomes in this vulnerable patient population.

Reference

1. Pop T.L., Sîrbe C., Benţa G., Mititelu A., Grama A. The role of vitamin D and vitamin D binding protein in chronic liver Diseases. Int. J. Mol. Sci. 2022;23:10705. doi: 10.3390/ijms231810705

2. Battistini C., Ballan R., Herkenhoff M.E., Saad S.M.I., Sun J. Vitamin D modulates intestinal microbiota in inflammatory bowel diseases. Int. J. Mol. Sci. 2020;22:362. doi: 10.3390/ijms22010362.

3. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007;357:266–281. doi: 10.1056/NEJMra070553.

4. Slominski A.T., Chaiprasongsuk A., Janjetovic Z., Kim T.K., Stefan J., Slominski R.M., Hanumanthu V.S., Raman C., Qayyum S., Song Y., et al. Photoprotective properties of vitamin D and lumisterol hydroxyderivatives. Cell Biochem. Biophys. 2020;78:165–180. doi: 10.1007/s12013-020-00913-6.

5. Giustina A., Bouillon R., Binkley N., Sempos C., Adler R.A., Bollerslev J., Dawson-Hughes B., Ebeling P.R., Feldman D., Heijboer A., et al. Controversies in vitamin D: A statement from the third international conference. JBMR Plus. 2020;4:e10417. doi: 10.1002/jbm4.10417.

6. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., Murad M.H., Weaver C.M. Endocrine society. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011;96:1911–1930. doi: 10.1210/jc.2011-0385.

7. Institute of Medicine . Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press; Washington, DC, USA: 2011. [PubMed] [Google Scholar]

8. Bouillon R., Manousaki D., Rosen C., Trajanoska K., Rivadeneira F., Richards J.B. The health effects of vitamin D supplementation: Evidence from human studies. Nat. Rev. Endocrinol. 2022;18:96–110. doi: 10.1038/s41574-021-00593-z.

9. Charoenngam N., Holick M.F. Immunologic effects of vitamin D on human health and disease. Nutrients. 2020;12:2097. doi: 10.3390/nu12072097.

10. Vojinovic J. Vitamin D receptor agonists' anti-inflammatory properties. Ann. N. Y. Acad. Sci. 2014;1317:47–56. doi: 10.1111/nyas.12429

11. Sirajudeen S., Shah I., Al Menhali A. A narrative role of vitamin D and its receptor: With current evidence on the gastric tissues. Int. J. Mol. Sci. 2019;20:3832. doi: 10.3390/ijms20153832.

12. Charoenngam N., Shirvani A., Kalajian T.A., Song A., Holick M.F. The effect of various doses of oral vitamin D3 supplementation on gut microbiota in healthy adults: A randomized, double-blinded, dose-response study. Anticancer Res. 2020;40:551–556. doi: 10.21873/anticanres.13984.

13. Ferder L., Martín Giménez V.M., Inserra F., Tajer C., Antonietti L., Mariani J., Manucha W. Vitamin D supplementation as a rational pharmacological approach in the COVID-19 pandemic. Am. J. Physiol. Lung Cell. Mol. Physiol. 2020;319:L941–L948. doi: 10.1152/ajplung.00186.2020.

14. Martín Giménez V.M., Inserra F., Ferder L., García J., Manucha W. Vitamin D deficiency in African Americans is associated with a high risk of severe disease and mortality by SARS-CoV-2. J. Hum. Hypertens. 2021;35:378–380. doi: 10.1038/s41371-020-00398-z.

15. Martín Giménez V.M., Lahore H., Ferder L., Holick M.F., Manucha W. The little-explored therapeutic potential of nanoformulations of 1,25-dihydroxyvitamin D3 and its active analogs in prevalent inflammatory and oxidative disorders. Nanomedicine. 2021;16:2327–2330. doi: 10.2217/nnm-2021-0284.